Category Archives: EQS Newsfeed

Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™

Posted on by
  • Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene therapy for pediatric and adult patients with transfusion dependent beta-thalassemia
  • Long-term collaboration began in 2013 and enabled commercial approval and rapid uptake for ZYNTEGLO™ in 2022

Basel, Switzerland, 9 March 2026 – Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Genetix Biotherapeutics Inc. (Genetix), a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced the extension of their long-term commercial manufacturing agreement. Under the expanded agreement, Lonza will expand manufacturing capacity to support growing demand for Genetix’s ZYNTEGLO™, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.

The extended agreement further strengthens the strategic collaboration established in 2013 between Lonza and Genetix, which later enabled ZYNTEGLO™ commercial approval in 2022. Under the renewed agreement, commercial manufacturing for Genetix will continue at Lonza’s Houston (US) facility, a dedicated cell and gene therapy site with nearly 10 years of combined clinical and commercial experience supporting the manufacture of this innovative treatment. The collaboration also makes provisions to scale up manufacturing in the future for additional Genetix therapies.

Daniel Palmacci, Head of Specialized Modalities at Lonza, said: “Our extended agreement with Genetix underscores the value of our services and expertise in commercial cell and gene therapy manufacturing. We are proud to continue our collaboration by expanding the commercial production of ZYNTEGLO™ at our state-of-the-art manufacturing facility in Houston.”

Brian Riley, President and Chief Technology Officer at Genetix, added: “Our long-standing partnership with Lonza reflects our shared commitment to commercial excellence and operational discipline to bring curative therapies to patients impacted by rare disease. Their scientific rigor, quality focus and consistent execution have been important in enabling a reliable supply of ZYNTEGLO™. In the last year, patient demand for Genetix’s therapies has grown consistently and rapidly. Extending the agreement with Lonza and expanding capacity provides a strong foundation as we invest to meet the growing patient demand and broaden our long-term manufacturing strategy.”

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

Posted on by

Heidelberg Pharma AG / Key word(s): Significant contracts

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

07-March-2026 / 02:03 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Ad hoc announcement – Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

  • Heidelberg Pharma is eligible to receive USD 20 million upfront funded by Soleus Capital, subject to closing conditions
  • USD 25 million to be funded by Soleus Capital upon FDA approval of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px; HCRx payment upon approval still in place

Ladenburg, Germany, 7 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.

In March 2024, Heidelberg Pharma entered into an agreement with HCRx for the sale of royalties on TLX250-Px up to a defined cap, which agreement was subsequently amended in March 2025. As part of the current amendment, Heidelberg has agreed to an increased cap on total payments alongside certain other contractual changes. The participation of Soleus Capital has no impact on the payments from HCRx.

Key terms of the agreement between Heidelberg Pharma, HCRx and Soleus Capital are:

  • Heidelberg Pharma will receive a USD 20 million payment under the amended agreement, funded by Soleus Capital, subject to customary closing conditions expected to be fulfilled shortly.
  • Heidelberg Pharma will receive another USD 25 million payment funded by Soleus Capital upon FDA approval of TLX250-Px. The calculation of the FDA approval milestone payment from HCRx under the existing agreement remains unchanged under this amendment.
  • Once the maximum cumulative amount of royalties sold is reached under the amended agreement, a high single-digit royalty tail percentage amount will be due under the amended agreement and remaining royalty payments will revert to Heidelberg Pharma.
  • Based on current planning, available funds and the today signed agreement, the Company’s financing will be secured until mid-2027.

End of Inside Information

Explanation, why the information directly concerns that issuer:

About TLX250-Px

TLX250-Px is a radiolabeled form of the antibody girentuximab, which binds to the tumor-specific antigen CAIX on ccRCC. Heidelberg Pharma developed the antibody up to a first completed Phase III clinical trial prior to licensing it to Telix Pharmaceuticals Limited (Telix), an Australian company based in Melbourne, in 2017.

About Heidelberg Pharma

Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. Heidelberg Pharma is open for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

About HealthCare Royalty

HealthCare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com.

HEALTHCARE ROYALTY®, HEALTHCARE ROYALTY PARTNERS® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

About Soleus Capital Management

Soleus Capital is a healthcare investment firm located in Greenwich, CT, USA, which manages hedge, private equity and credit funds primarily focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics.

Contact
Heidelberg Pharma AG
Sylvia Wimmer
Senior Director Corporate Communications
Tel.: +49 89 41 31 38-29
E-Mail: investors@hdpharma.com
Gregor-Mendel-Str. 22, 68526 Ladenburg		  
IR/PR-Support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
E-Mail: katja.arnold@mc-services.eu

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

07-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 – 0
Fax: +49 (0)89 41 31 38 – 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2287470

 
End of Announcement EQS News Service

2287470  07-March-2026 CET/CEST

Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients

Posted on by
  • Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing. The transaction is expected to close in H2 2026
  • Lonza will receive upfront proceeds of CHF 1.7 billion (USD 2.2 billion) and retain a 40% stake in CHI, with an additional preferential participation in a future exit
  • Total undiscounted proceeds, including upfront and all future proceeds at full exit, are expected to be at or above CHF 3 billion (~USD 4 billion)
  • With the divestment of CHI, Lonza delivers on its commitment to transform into a pure-play CDMO, focused on value creation from high growth and expanding margins in its world-leading CDMO business
  • Lonza plans to invest the upfront proceeds into additional organic growth opportunities in line with the One Lonza Strategy, as well as bolt-on acquisitions. CHF 500 million will be returned to shareholders through a share buyback following receipt of proceeds
  • As part of its wider portfolio transformation, Lonza has also signed agreements to divest the Personalized Medicines business (the Cocoon® Platform), the MODA® software platform, and the small molecules micronization site in Monteggio (CH)

Basel, Switzerland, 6 March 2026 – Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds (“Lone Star”) for an enterprise value of CHF 2.3 billion (USD 3 billion). Lonza will realize upfront cash proceeds of CHF 1.7 billion (USD 2.2 billion) and retain a 40% stake in the business, with additional preferential participation in its future exit. Lonza’s proceeds on exit are subject to Lone Star receiving an initial return equal to its equity investment. The combination of significant upfront proceeds with the preferential participation in future exit proceeds and the sale of the retained stake in CHI at future exit provide an attractive value upside and future cash generation. Considering the leading position and strengths of the CHI business after its return to growth in 2025, the total undiscounted value of the proceeds for Lonza from the full exit from CHI, including upfront proceeds, proceeds from future sale of its retained 40% stake and preferential participation in exit proceeds, is expected to be at or above CHF 3 billion (~USD 4 billion).

The transaction is the last and most significant step to complete Lonza’s strategic portfolio transformation to a pure-play CDMO. Wider portfolio updates include agreements to divest the Personalized Medicines business including the Cocoon® Platform to Octane Medical Group, the MODA® software platform to the parent company of STARLIMS Corporation, and the small molecules micronization site in Monteggio (CH) to Microsize and Schedio Group. As a result, Lonza now operates across three complementary and integrated CDMO Business Platforms, all powered by the Lonza Engine® as their unique set of strengths, leveraging cutting-edge science, smart technology and lean manufacturing for complex and emerging pharmaceutical modalities.

Wolfgang Wienand, CEO, Lonza commented: “With the sale of CHI and the three other recent divestments, in less than two years we have reshaped our company and activated our vision of One Lonza as a pure-play CDMO. We are now able to laser-focus on where we are strongest and can create most value for our customers, people and shareholders. On top of receiving significant upfront proceeds for re-investment in our world-leading CDMO business, we have been able to implement attractive mechanisms for Lonza to benefit from future value creation by CHI. Following a rigorous process, we are confident that Lone Star brings the necessary capabilities to lead CHI into a good future and create opportunities for the colleagues departing from Lonza. I thank the whole CHI team for their commitment to Lonza over many years and their continued support in the upcoming transition phase.”

With execution of the transactions, Lonza delivers on the commitment made at its December 2024 Investor Update as part of the new One Lonza Strategy to fully focus on high value creation within its CDMO Organic Growth Model™ of low teens CER sales growth on average over time at expanding margins, while investing mid-to-high teens percentages of sales. The proceeds from the CHI exit will become part of Lonza’s discretionary cash pool in its defined capital allocation framework to fund prioritized organic growth opportunities and bolt-on acquisitions with attractive return profiles, adding capacities, technologies and expanding its business portfolio in line with the One Lonza Strategy and competitive differentiation driven by the Lonza Engine®.

Lonza is committed to further strengthening cash generation, applying high discipline in capital allocation and maintaining an efficient capital structure. Given the expected moderation of organic capital expenditures to mid-to-high teens percentages of sales in the mid-term and the upfront proceeds from the sale of CHI, the company’s leverage is anticipated to be materially below target levels. Balancing near-term surplus capital with its conviction that attractive investment opportunities can be identified and executed over the mid-term, Lonza will return CHF 500 million to shareholders via a share buyback which will be executed after receipt of the upfront proceeds. On an ongoing basis, Lonza will review the outlook for strategically and financially attractive investments and determine whether the level of capital maintained is appropriate for likely requirements. Any capital deemed to be surplus will be returned to shareholders.

Lonza remains committed to its progressive1 dividend policy, maintaining or growing its dividend per share year-on-year, while maintaining leverage levels and a credit profile consistent with its Standard & Poor’s investment grade credit profile of BBB+ which has been consistently reaffirmed since 2019.

Lone Star has an established track record of reaching the full potential of its portfolio companies with similar characteristics to CHI by empowering management and investing for the future. Lone Star has confirmed that maintaining high standards of service delivery and quality for customers are a core foundation of their strategy for CHI following closing.

The retained interest in CHI will be accounted for as an investment in an associated company with Lonza as a minority shareholder not having management control. Lonza estimates that it will recognize an extraordinary non-cash impairment including the goodwill related to CHI assets of around CHF 1.3 billion in its Financial Statements for Financial Year 2025 to be published on 1 April2026. This effect will be allocated to discontinued operations and will not impact CORE EBITDA of continuing operations.

The transaction is expected to close in H2 2026, subject to customary closing conditions relating to regulatory approvals and completion of the legal separation of CHI from Lonza’s wider business.

BofA Securities and Centerview Partners acted as joint financial advisors to Lonza.

For more details on the transaction, please refer to the related Investor Presentation.

Investor Call Details
Lonza invites investors to join a live webcast and conference call on Friday 6 March 2026 at 19:00 CET or on Monday 9 March 2026 at 08:00 CET. In both calls, our CEO Wolfgang Wienand and our CFO Philippe Deecke will share a short presentation with details of the transaction, and take questions from investors. Both calls are scheduled to last for 30 minutes.

19:00 CET, Friday 6 March 2026 call details:
Access to webcast
In order to follow the slide presentation and the Q&A session, please use the webcast link.

Access to conference call
The presentation will be followed by a Q&A session. You can register to ask questions over the conference call at any time during the event. You will receive the relevant phone numbers, a passcode and your personal PIN to access the conference call by pre-registering here.

08:00 CET, Monday 9 March 2026 call details:
Access to webcast
In order to follow the slide presentation and the Q&A session, please use the webcast link.

Access to conference call
The presentation will be followed by a Q&A session. You can register to ask questions over the conference call at any time during the event. You will receive the relevant phone numbers, a passcode and your personal PIN to access the conference call by pre-registering here.

Should you have any access issues, please dial the following numbers 10 to 15 minutes prior to scheduled start:
+41 (0) 58 310 50 00 (Europe and Switzerland) 
+44 (0) 207 107 06 13 (UK) 
+1 631 570 56 13 (USA)  

Other international numbers are available here. 
 

1 Maintaining or increasing dividend per share each year.

Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025

Posted on by

Eckert & Ziegler SE / Key word(s): Dividend payments

Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025

06-March-2026 / 10:36 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Berlin, 6 March 2026. The Executive Board of Eckert & Ziegler (ISIN DE0005659700, TecDAX) intends to propose to the Annual General Meeting a dividend of € 0.22 per share for the 2025 financial year (previous year, split adjusted: € 0.17). The Supervisory Board will decide on the proposal for the appropriation of profits at its regular meeting on the company’s annual financial statements. The dividend payment is subject to the resolution of the Annual General Meeting.

The detailed annual financial statements for 2025 will be published on March 26, 2026.

For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

End of Inside Information

06-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2286894

 
End of Announcement EQS News Service

2286894  06-March-2026 CET/CEST

Appointment of Falk Neukirch as Chief Financial Officer to expire on April 30, 2026

Posted on by

Medios AG

/ Key word(s): Personnel

Appointment of Falk Neukirch as Chief Financial Officer to expire on April 30, 2026

06.03.2026 / 08:17 CET/CEST

The issuer is solely responsible for the content of this announcement.

Press release

Appointment of Falk Neukirch as Chief Financial Officer to expire on April 30, 2026

Berlin, March 6, 2026 – The Supervisory Board of Medios AG announces that the appointment of Falk Neukirch as Chief Financial Officer (CFO) of Medios AG will not be extended beyond the end of his current term in April 2026 at his own request.

Following the successful repositioning and international expansion of the Medios Group, Falk Neukirch has decided to pursue new professional opportunities. This also provides the opportunity to realign the Group’s leadership structure under the leadership of the new Chief Executive Officer (CEO), Thomas Meier.

Since the beginning of his tenure in October 2021, which was extended in May 2023 until April 2026, Mr. Neukirch has played a key role in shaping and advancing the development of the Medios Group. In particular, he elevated systems, processes and structures in the areas of finance and controlling to a new level, significantly enhancing transparency and steering capability across the Group. This included, among other achievements, the successful implementation of a new ERP system, the rollout of which commenced in January 2026.

In addition to operational improvements, Mr. Neukirch made a substantial contribution to the successful execution of several significant acquisitions and the swift integration of the acquired entities into the Medios Group’s finance organization. This particularly included the acquisition and integration of the CEBAN Group in 2024, during which more than 50 entities were successfully integrated into the finance function within a very short period of time. In this context, under Mr. Neukirch’s leadership, long-term bank financing in the amount of €225 million was secured.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: “Falk Neukirch has played a decisive role in shaping Medios’ development since 2021 and has made important contributions to the further advancement of our organization. With strong financial expertise and strong commitment, he has sustainably strengthened the finance function and made a significant contribution to the transparency and stability of the Group. He has also provided decisive support to the Company’s positive development through his involvement in strategically important projects and acquisitions.”

The Supervisory Board expressly thanks Mr. Neukirch for the trusting and constructive cooperation, his dedication and his valuable contribution to the positive development of the Medios Group. During a key phase of transformation, Mr. Neukirch advanced the Group with prudence and a high level of professional expertise.

To ensure a smooth handover of responsibilities, Mr. Neukirch will remain available to the Company in an advisory capacity on a transitional basis.

Important events for Medios AG in the 2026 financial year:

March 26 Annual Report 2025
May 12 Quarterly Statement as of 31 March 2026
June 10 Ordinary Annual General Meeting 2026
August 12 Half-Year Financial Report 2026
November 10 Quarterly Statement as of 30 September 2026

——————-

About Medios AG

Medios is a leading provider of specialty pharmaceuticals in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on future-oriented individual medicine to enable all people to receive the most innovative therapies together with pharmacies, specialist practices, and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) and are listed in the SDAX selection index.

www.medios.group

More information on the topic of individual medicine: https://app.medios.group/individualmedizin

 

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

ir@medios.group

www.medios.group

 

Disclaimer

This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ materially from those currently anticipated due to various risk factors and uncertainties, such as changes in business, economic and competitive conditions, exchange rate fluctuations, uncertainties regarding litigation or investigations, and the availability of funds. Medios AG assumes no responsibility to update the forward-looking statements contained in this release.

06.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: +49 30 232 566 – 801
E-mail: ir@medios.group
Internet: www.medios.group
ISIN: DE000A1MMCC8
WKN: A1MMCC
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2286870

 
End of News EQS News Service

2286870  06.03.2026 CET/CEST

Cellbox Solutions closes first tranche of Series A financing and appoints new CBO/CFO to accelerate international growth

Posted on by

Cellbox Solutions GmbH

/ Key word(s): Financing/Personnel

Cellbox Solutions closes first tranche of Series A financing and appoints new CBO/CFO to accelerate international growth

05.03.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Cellbox Solutions closes first tranche of Series A financing and appoints new CBO/CFO to accelerate international growth

  • Companisto leads ~EUR 3.5 million investment round to scale Cellbox’s™ global warm-chain logistics platform
  • Dr. Bernd Muehlenweg joins as Chief Business Officer and Chief Financial Officer to drive international expansion and service portfolio growth

Cologne, Germany, March 5, 2026 – Cellbox Solutions, a warm-chain logistics technology company enabling the global transport of living cells under controlled physiological conditions, today announced the first closing of its Series A financing round, raising approximately EUR 3.5 million. The round is led by the digital business angel network Companisto, together with existing investors, including NRW.BANK. The new capital will be used to expand international production and sales activities and to unlock additional application areas, particularly in cell and gene therapy as well as in vitro fertilization (IVF). In addition, the management team is strategically strengthened with the appointment of Dr. Bernd Muehlenweg to further drive growth and scalability. This is the first closing of a Series A financing round which remains open for other tranches until May 2026.

Cellbox™ develops portable CO₂ incubators for the safe transport of living cell samples. Its patented warm-chain technology enables continuously controlled shipment conditions for up to 48 hours, preserving cell viability and functionality during transport. The systems are certified and compliant with IATA regulations for air transport. More than 300 devices are already in use worldwide by leading customers in the pharmaceutical and biotechnology industries, applied research institutions, and universities.

A key component of this next growth phase is the appointment of Dr. Bernd Muehlenweg as Chief Business Officer (CBO) and Chief Financial Officer (CFO) of Cellbox™. He joins the company full-time with more than 20 years of international experience in the life sciences industry. Most recently, Dr. Muehlenweg served as Senior Vice President and Global Head of Business Development, Cell Therapy at Evotec, where he led international commercial and strategic partnership activities in the advanced therapy space.

“Cellbox™ is setting a new benchmark in the transportation of living cells. By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry. The investment round marks an important milestone in expanding our international footprint and establishing Cellbox™ as a global infrastructure standard for living cell shipment and warm-chain logistics. Our patented platform and strong regulatory positioning provide an excellent foundation for global scale-up across multiple life sciences applications, including the rapidly growing field of cell and gene therapies. I look forward to further strengthening our commercial operations, expanding our service portfolio, and building the organizational structures required to support the next phase of international growth,” commented Dr. Bernd Muehlenweg, CBO & CFO of Cellbox Solutions GmbH.

“Cellbox™ addresses a structural gap in the life sciences value chain: the reliable transport of living cells at physiological conditions. As advanced therapies scale globally, logistics becomes a critical success factor. We view Cellbox™ not as an incremental product innovation, but as a scalable platform with the potential to redefine how sensitive biological materials are transported across research and clinical environments,” added Dr. Robin Ghosh, Investment Manager at Companisto.

Companisto will actively support Cellbox™ in its next growth phase. As a fully digitalized business angel network, Companisto contributes not only capital but also targeted strategic expertise to international scaling.

“Our vision is to redefine how living cells are transported globally. With the continued support of our investors and the strengthening of our leadership team with a highly experienced executive, we are building the foundation for long-term international growth and expanding the reach of warm-chain logistics across clinical and research applications. We are convinced that reliable live-cell transport will become an essential component of the global life sciences value chain,” concluded Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox™.

In the long term, Cellbox™ aims to establish warm-chain logistics as the preferred global approach for transporting living cells, cell therapies, and sensitive biological materials, further advancing reliability and reproducibility across the life sciences sector.

About Cellbox Solutions GmbH

Founded in 2017, Cellbox Solutions GmbH is a Germany-based warm-chain logistics technology company providing innovative solutions for the global healthcare and life sciences industries to transport sensitive biological materials and therapeutics that cannot be frozen and require controlled physiological conditions. The company’s portable CO₂ incubator platform, Cellbox™, creates a regulated environment for the transport of living cells, organoids, tissues, and other advanced biological materials. Temperature and CO₂ levels are individually adjustable to ensure reproducible incubation conditions throughout shipment. Cellbox™ systems are deployed globally and support research, clinical, and advanced therapy applications. For more information, please visit www.cellbox-solutions.com or follow Cellbox Solutions on LinkedIn.

About Companisto

Companisto is a digital business angel network that enables private and institutional investors to participate in venture capital investments in innovative growth companies. Since its founding, Companisto has successfully financed numerous startups and growth-stage companies and actively supports them with capital, expertise, and a strong investor community.

Contacts

Prof. Dr. Kathrin Adlkofer, CEO Cellbox™
office@cellbox-solutions.com
Sophie Schultheiss, Companisto
presse@companisto.com
+49 (0)30 208 484 957

Media inquiries

MC Services AG

Dr. Cora Kaiser
cellbox@mc-services.eu
+49-(0)89 210 228 60

05.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

2286304  05.03.2026 CET/CEST

BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call

Posted on by

Basel, Switzerland. March 5, 2026, 7am CET.

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the reporting of its Full Year 2025 financial results, along with a business update and the hosting of an investor, analyst and media conference call.

 

The company will publish its Full Year 2025 financial results on March 18, 2026. On the reporting date, BioVersys will issue a press release at 7:00 AM CET / 2:00 AM ET.

 

Following the release, BioVersys will host a conference call and webcast on March 18, 2026 at 2:00 PM CET / 9:00 AM ET where management will review the financial results, provide a business update, outline its strategic outlook and where investors, analysts and journalists will be able to ask questions.

 

Details of the conference call and webcast:

 

  • Conference Call Registration: Link (Participants will receive dial-in details upon registration)

 

 

Important Note: Participants joining the conference call are kindly asked to mute their browser audio during the session.

 

 

About BioVersys

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ongoing), and tuberculosis (alpibectir, Phase 2b, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

 

 

BioVersys contact

Hernan Levett, CFO

Tel. +41 61 633 22 50

Mail: Hernan.levett@bioversys.com

Anca Cighi, Investor Relations and Communications

Tel. +41 61 551 24 39

Mail: anca.cighi@bioversys.com

 

For Media: media@bioversys.com

www.bioversys.com

 

 

 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Formycon AG publishes preliminary figures for the 2025 fiscal year

Posted on by

Formycon AG / Key word(s): Results / Full year/Other

Formycon AG publishes preliminary figures for the 2025 fiscal year

04-March-2026 / 22:50 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Formycon AG publishes preliminary figures for the 2025 fiscal year

  • Strong increase in Group revenues in the fourth quarter, but full-year revenues still expected to remain below guidance
  • Group EBITDA expected to be at the upper end of the expected range
  • Adjusted EBITDA as well as working capital expected to be improved versus guidance

Planegg-Martinsried, Germany, March 4, 2026 – Based on preliminary and unaudited figures, Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) (“Company” or “Formycon“) expects Group revenues for the 2025 fiscal year to amount to approximately € 45 million. Despite a strong increase in the fourth quarter, total revenues are below the previously communicated forecast range of € 55 million to € 65 million. This is partly due to longer negotiations to conclude further commercialization and development partnerships, for example for the Keytruda®1 biosimilar candidate FYB206, in order to optimize their financial terms. In addition, recognition of milestone events anticipated for Q4 shifted to the first quarter of 2026. Furthermore, while revenue contributions from FYB202 increased significantly in Q4, the product is still in the early phase of commercialization and did not ramp up as quickly as expected.

In this context, based on the results of the impairment test available to date, the company expects that the valuation model and balance sheet measurement for FYB202 will need to be reviewed and adjusted to reflect this slower ramp up. According to Formycon’s commercialization partners, market uptake of FYB202 is developing positively. However, despite encouraging political signals, the pharmacy benefit market (PBM) in the U.S. is still opening only gradually. Based on preliminary calculations, the company expects an extraordinary, non-cash and non-EBITDA-relevant impairment requirement in the low to mid double-digit million range.

The Group’s earnings before interest, taxes, depreciation and amortization (Group EBITDA) for the 2025 fiscal year is expected to amount to approximately € -12 million, at the upper end of the forecast range of € -20 million to € -10 million. Adjusted consolidated earnings before depreciation and amortization (Group adjusted EBITDA), which also shows the total income of the FYB201 ranibizumab biosimilar, is expected to be approximately € -7 million, which is above the most recently communicated forecast range of € -20 million to € -10 million. The significantly better-than-expected at-equity result (approx. € 5 million) from the 50% stake in Bioeq AG mainly benefited from the upfront payment from the partnership of FYB201/Nufymco®2.

The Company expects a further improvement in working capital to approximately € 73 million, which is significantly above guidance. Due to the € 70 million corporate bond placed in July 2025, Formycon had already raised its forecast for this key figure from the original € 25 million to € 35 million to € 55 million to € 65 million upon publication of its half-year results for 2025. Significant upfront payments in connection with initial partnerships for the Keytruda® biosimilar candidate FYB206 in 2025, strict cost management and efficiency improvements contributed to a further increase.

The final financial figures and further information on the 2025 financial year as well as the outlook for 2026 will be published on 26 March 2026 with the annual report for the 2025 financial year on the website under Publications – Formycon AG .

————-

  1. Keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ/USA
  2. Nufymco® is a registered trademark of Formycon AG

Contact
Sabrina Müller
Director Investor Relations & Corp. Communications
Formycon AG,
Fraunhoferstraße 15,
82152 Planegg/Martinsried,
Germany

Phone +49 (0) 89 – 86 46 67 149 | Fax + 49 (0) 89 – 86 46 67 110
ir@formycon.com // www.formycon.com

Disclaimer

Certain statements contained in this release may constitute “forward-looking statements” that involve a number of risks and uncertainties. Forward-looking statements can generally be identified by the use of the words “may”, “will”, “should”, “plan”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “project”, or “target” or the negative of these words or other variations of these words or comparable terminology. Forward-looking statements are based on assumptions, forecasts, estimates, predictions, opinions or plans that are inherently subject to significant risks, uncertainties and uncertainties that are subject to change. The Company makes no representation and does not make any representation that any forward-looking statement will be achieved or prove to be accurate. Actual future business, financial condition and results of operations and prospects may differ materially from those projected or projected in the forward-looking statements. Subject to applicable legal requirements, neither the Company nor any other person intends to update, review, revise or conform to actual events or developments any forward-looking statements contained in this announcement, whether as a result of the availability of new information, new developments in the future or otherwise, nor does they assume any such obligation.

End of Inside Information

04-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: +49 89 864667 100
Fax: +49 89 864667 110
E-mail: ir@formycon.com
Internet: www.formycon.com
ISIN: DE000A1EWVY8, NO0013586024
WKN: A1EWVY, A4DFJH
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX; Oslo
EQS News ID: 2285968

 
End of Announcement EQS News Service

2285968  04-March-2026 CET/CEST

BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy

Posted on by

 

Basel, Switzerland. March 04, 2026, 7am CET

 
  • BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data.
  • BV100 demonstrated a dose-proportional pharmacokinetic profile and was generally safe and well tolerated.
  • BV100 global Phase 3 clinical trial is initiated with read-out expected in H2 2027.
  • Additional Phase 2b to demonstrate clinical differentiation and further de-risk BV100’s registrational path to be initiated in 2026 with interim data read-out expected end of 2026.

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, the publication of Phase 1, single- and multiple-ascending dose (SAD and MAD) clinical trial data including pharmacokinetics, safety and tolerability of BV100 in healthy volunteers in the Journal of Antimicrobial Agents and Chemotherapy.[1]

BV100 is a novel intravenous formulation of rifabutin based on the newly identified mode of action for the active uptake of rifabutin into the Acinetobacter baumannii-calcoaceticus complex. BV100 is being developed for MDR hospital infections caused by Acinetobacter baumannii, including carbapenem-resistant strains.

BV100 demonstrated a dose-proportional PK profile and was generally safe and well tolerated. Based on these positive results, BV100 doses of 200-300 mg administered every 12 hours have been evaluated in a Phase 2 clinical trial in Ventilator Associated Bacterial Pneumonia (VABP) patients, for treating carbapenem-resistant A. baumannii (CRAB) infections. BV100 demonstrated a clear survival benefit, resulting in a 50% relative reduction in all-cause mortality (ACM) in VABP patients suffering from CRAB infections compared with best available therapy (BAT), and was generally safe and well tolerated.

In December 2025, BV100 advanced into a global registration Phase 3 clinical trial (RIV-TARGET), in HABP/VABP patients suffering from CRAB infections, employing a similar  study design to the successful Phase 2 trial. The first patient is expected to be dosed in the coming weeks, and Phase 3 read-out is expected in H2 2027.

A global open-label Phase 2b clinical differentiation trial (RIV-CARE) will be initiated in H1 2026 and will compare BV100 with best available therapy in multiple geographies. Primary efficacy, safety and secondary endpoints will be similar to the Phase 3 trial described above. An interim analysis of the Phase 2b trial is expected towards end 2026.

Dr. Glenn E Dale, Chief Development Officer: “Multi-drug resistant infections, especially those acquired in a hospital setting are a rising medical problem across healthcare systems worldwide. Following the regulatory interactions we have had with the FDA and the CHMP, we continue to make progress with our antibiotic candidate, BV100. We are now advancing BV100 into global registrational study program with our two trials RIV-TARGET and RIV-CARE. As the RIV-CARE trial will be open-label, we are looking forward to first interim data towards end 2026.”

About BV100

BV100 is a novel formulation of rifabutin suitable for intravenous administration, with a recently discovered novel mode of action showing an active uptake of rifabutin into the Gram-negative bacterial species, Acinetobacter baumannii. For the first time, the BV100 allows for the targeting of the RNA-polymerase enzyme in Gram-negative bacteria with a human-suitable dose. BV100 is being developed for the treatment of infections caused by Acinetobacter baumannii calcoaceticus complex (ABC), including Carbapenem-Resistant ABC (CRAB) in critically important indications of ventilator associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI). BV100 was granted QIDP Designation by the U.S. FDA in May 2019 for use in the treatment of VABP, HABP and BSI, making BV100 eligible for priority FDA review, Fast Track designation, and a five-year extension of market exclusivity upon approval of the first QIDP indication.

 

About Acinetobacter baumannii

Acinetobacter baumannii calcoaceticus complex (ABC) are Gram-negative bacteria found in the environment (e.g., in soil and water) and an opportunistic pathogen in humans, typically infecting critically ill and immunocompromised patients, that can result in severe pneumonia and bloodstream infections in addition to affecting other parts of the body. ABC is considered a significant worldwide threat in the healthcare setting given its ability to survive for prolonged periods on surfaces, combined with its ability to develop or acquire resistance to standard of care antibiotics, e.g. carbapenems. Carbapenem-resistance as well as multi-drug resistance (MDR) rates for ABC are among the highest recorded for any bacteria in current times (The Lancet 2022; 399: 629–55). Incidence and resistance rates for ABC are trending upwards and COVID-19 has exacerbated this significantly. BioVersys forecasts the annual number of carbapenem-resistant A. baumannii infections in hospitals to have surpassed one million globally and due to the limited treatment options, such infections come with high (up to 50%) mortality rates.

 

About BioVersys

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

BioVersys contact 
Hernan Levett, CFO, Tel. +41 61 633 22 50; Mail: hernan.levett@bioversys.com
For media: media@bioversys.com Website: www.bioversys.com

 

 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

[1] Single- and Multiple-ascending Dose Study of the Pharmacokinetics, Safety and Tolerability of BV100 (rifabutin for infusion) in Healthy Volunteers; Christian Kemmer et al, 2026. https://journals.asm.org/doi/10.1128/aac.01582-25

Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology

Posted on by

Viromed Medical AG

/ Key word(s): Takeover

Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology

04.03.2026 / 07:44 CET/CEST

The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology

Rellingen, March 04, 2026 – Viromed Medical AG (“Viromed“; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has signed a letter of intent to acquire relyon plasma GmbH (“relyon”). The Regensburg-based company is a subsidiary of TDK Electronics AG and is one of the leading technology providers in the field of atmospheric plasma technology.

relyon develops modular systems and customized OEM components for industrial and medical applications. The company also has an extensive international patent portfolio in the field of plasma technology. In recent years, relyon has collaborated with Viromed to develop the ViroCAP® and PulmoPlas® cold plasma medical device product families and currently manufactures these systems on behalf of Viromed.

Uwe Perbandt, CEO of Viromed Medical AG, explains: “With the planned integration of relyon, we are strengthening our technological sovereignty and significantly increasing our value creation depth. We are combining an extensive patent portfolio, development expertise, and manufacturing capacity in an integrated structure, thereby laying the foundation for more efficient scaling. Combined with our medical expertise and market penetration, this will result in an integrated plasma platform that is unique internationally in this form. This underscores our ambition to play a leading role in the global market for atmospheric cold plasma technology. Our goal is to further industrialize this technology internationally and position Viromed as an integrated provider with high technological and industrial expertise in the long term.”

Strategic integration along the value chain

The proposed transaction aims to substantially expand Viromed’s technological and industrial base in the field of atmospheric cold plasma technology. Subject to completion, relyon’s research, development, industrial manufacturing, and international patent portfolio would be brought together for the first time in a closely integrated structure. Through this vertical integration, Viromed will increase its control over key stages of the value chain, reduce its dependence on external development and production services, and create the structural conditions for further development of the technology.

Strengthening the technological position

With direct access to relyon’s patent portfolio, Viromed is also expanding its patent base and securing its long-term technological development. The combination of medically validated application expertise, engineering expertise, and industrial vertical integration raises the barriers to market entry. This improves Viromed’s strategic starting position for further growth and strengthens its international competitiveness in a technology-driven market environment.

Positioning in a growth market

Atmospheric cold plasma technology can be deployed across a wide range of applications, including broad use in medicine, in industrial processes, and, looking ahead, in related areas such as agricultural and water technology. Long-term drivers such as increasing regulatory requirements, sustainability goals, and the growing relevance of antimicrobial solutions support the market potential. With the planned transaction, Viromed aims to strategically expand its position in this environment and strengthen the foundation for sustainable, scalable growth.

Details of the transaction

The purchase price is currently under negotiation, but Viromed estimates that it will be in the low to mid double-digit million euro range. The conclusion of the corresponding share purchase agreement and the completion of the transaction are expected in the second quarter of 2026 and will be subject to a successful due diligence review and the fulfillment of customary closing conditions.

 

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

 

Contact Viromed

E-Mail: kontakt@viromed-medical.de

 

Press contact

E-Mail: viromed@kirchhoff.de

04.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
EQS News ID: 2285022

 
End of News EQS News Service

2285022  04.03.2026 CET/CEST